Flash Finance

Akums Drugs and Pharmaceuticals LimitedAKUMSCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 13 quarters of data
Consolidated Standalone
₹731.45
MCap ₹11,199 Cr · P/E 38.3
Akums Drugs and Pharmaceuticals Limited — Stock analysis & AI research Akums Drugs and Pharmaceuticals Limited — Seasonality — best & worst months Akums Drugs and Pharmaceuticals Limited — Technical indicators & charts Akums Drugs and Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Akums Drugs and Pharmaceuticals Limited — Live exchange announcements
📋 High Promoter Holding Stocks 📈 SuperTrend Bearish Signal📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,167 Cr
Sales · Jun 2026
+13.9% YoY
₹175 Cr
Operating Profit · Jun 2026
+35.4% YoY
15.0%
OPM % · Jun 2026
+19.0% YoY
₹101 Cr
Net Profit · Jun 2026
+56.1% YoY
₹6.53
EPS · Jun 2026
+57.3% YoY

📝 Akums Drugs and Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,167 crore for the quarter ended June 2026 (Q1 FY27), up 13.9% from ₹1,024 crore in the same quarter last year, and up 0.8% sequentially over the March 2026 quarter.

Net profit rose 56.1% year-on-year to ₹101 crore, from ₹65 crore. Earnings per share (EPS) came in at ₹6.53.

Operating profit stood at ₹175 crore — an operating margin (OPM) of 15.0%, compared with 12.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Akums Drugs and Pharmaceuticals Limited posted revenue of ₹4,359 crore, a growth of 5.9% over FY25, with a net profit of ₹256 crore (down 25.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹4,502 crore with a net profit of ₹293 crore.

Valuation snapshot

At the current price of ₹731.45, AKUMS has a market capitalisation of ₹11,199 crore and a trailing P/E of about 38.3.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 75.26%, foreign institutional investors (FIIs) 1.38%, domestic institutional investors (DIIs) 14.36%, public shareholders 6.29% of Akums Drugs and Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹11,199 Cr
Current Price ?
₹731.5
P/E ?
38.26above ind
Industry P/E ?
37.20
P/B ?
3.38
P/S ?
2.49
P/FCF ?
11.69
Enterprise Value ?
₹11,356 Cr
EV/EBITDA ?
20.00
PEG ?
1.32
Earnings Yield ?
3.6%
Dividend Yield ?
0.13%
Profitability & Returns
Sales (TTM) ?
₹4,502 Cr
OPM ?
12.6%
Profit after tax (TTM) ?
₹293 Cr
EPS (TTM) ?
₹19.12
ROCE ?
15.0%
ROE ?
8.8%
ROA ?
5.4%
Growth
Sales — latest qtr ?
₹1,167 Cr
PAT — latest qtr ?
₹101 Cr
YoY qtr sales growth ?
13.9%
YoY qtr profit growth ?
56.1%
Sales growth (3y) ?
6%
Sales growth (5y) ?
10%
Profit growth (3y) ?
29%
Profit growth (5y) ?
16%
Financial Health
Debt ?
₹157 Cr
Debt to Equity ?
0.05
Interest Coverage ?
3.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
75.26%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
10.0%
Return 6 months ?
34.0%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 9701,1811,0839441,0191,0331,0101,0561,0241,0181,1601,1581,167 +13.9% +0.8%
Operating Profit -1251529331281211219412994147152175 +35.4% +15.1%
Other Income 8-21101071715182732343530 +13.7% -13.9%
Interest 121412121312552323242425 +7.0% +3.6%
Depreciation 30303234343545403738404041 +11.2% +2.4%
Profit Before Tax -1598759-33879291759666100121139 +45.6% +14.9%
Net Profit -18733195-3961676615065436881101 +56.1% +24.1%
EPS -13.162.2213.54-2.894.214.144.269.644.152.664.335.536.53 +57.3% +18.1%
OPM % -12.9% 12.9% 8.6% 0.3% 12.6% 11.7% 12.0% 8.9% 12.6% 9.3% 12.7% 13.1% 15.0% +19.0% +14.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹4,118 Cr ₹4,359 Cr ₹4,502 Cr +5.9%
Operating Profit ₹464 Cr ₹522 Cr ₹568 Cr +12.4%
OPM % 11.27% 11.98% 12.61% +6.3%
NPM % 8.36% 5.88% 6.50% -29.7%
Other Income ₹56 Cr ₹129 Cr ₹132 Cr +131.3%
Depreciation ₹154 Cr ₹155 Cr ₹159 Cr +0.6%
Interest ₹35 Cr ₹94 Cr ₹96 Cr +171.1%
EBIT ₹311 Cr ₹367 Cr ₹409 Cr +18.3%
PBT ₹346 Cr ₹382 Cr ₹426 Cr +10.5%
Tax ₹-23 Cr ₹126 Cr ₹133 Cr +636.1%
Net Profit ₹344 Cr ₹256 Cr ₹293 Cr -25.5%
EPS ₹22.25 ₹16.67 ₹19.05 -25.1%
Material Cost ₹1,839 Cr ₹2,500 Cr ₹2,639 Cr +36.0%
Employee Cost ₹536 Cr ₹754 Cr ₹779 Cr +40.7%
Extraordinary Items ₹13 Cr ₹16 Cr ₹16 Cr +26.4%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 29293131 +0.0%
Reserves 6896813,0163,283 +8.9%
Borrowings 61956588157 +78.4%
Other Liabilities 1,9052,2299601,976 +105.8%
Total Liabilities 3,2413,5044,0955,447 +33.0%
Fixed Assets 1,0971,1911,3971,457 +4.3%
CWIP 103195163177 +8.6%
Investments 0000 —
Other Assets 2,0412,1182,5353,814 +50.5%
Total Assets 3,2413,5044,0955,447 +33.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1774984651,181 +154.0%
Cash from Investing Activity -305-331-548-930 -69.7%
Cash from Financing Activity 125-1087334 -53.4%
Net Cash Flow -459-10285 +2950.0%
Free Cash Flow -110212201958 +376.6%
CFO/OP 93%455%118%243% +105.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 84736867 -1.5%
Inventory Days 11790102110 +7.8%
Days Payable 91769687 -9.4%
Cash Conversion Cycle 111877489 +20.3%
Working Capital Days 46407166 -7.0%
ROCE % 22%2%16%15% -6.2%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 75.26%75.26%75.26%75.26% +0.0%
FIIs 4.24%2.27%1.14%1.38% +21.1%
DIIs 8.85%9.28%14.41%14.36% -0.3%
Public 8.92%10.46%6.45%6.29% -2.5%
Others 2.73%2.73%2.73%2.73% +0.0%
No. of Shareholders 69,42475,36576,86972,589 -5.6%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Akums Drugs and Pharmaceuticals Limited's revenue in Q1 FY27?
Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,167 crore for the quarter ended June 2026 (Q1 FY27), up 13.9% from ₹1,024 crore in the same quarter last year, and up 0.8% sequentially over the March 2026 quarter.
What was Akums Drugs and Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 56.1% year-on-year to ₹101 crore, from ₹65 crore. Earnings per share (EPS) came in at ₹6.53.
What is AKUMS's market capitalisation and P/E ratio?
At the current price of ₹731.45, AKUMS has a market capitalisation of ₹11,199 crore and a trailing P/E of about 38.3.
Who owns Akums Drugs and Pharmaceuticals Limited? (shareholding pattern)
As of Mar 2026, promoters held 75.26%, foreign institutional investors (FIIs) 1.38%, domestic institutional investors (DIIs) 14.36%, public shareholders 6.29% of Akums Drugs and Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI